Moderna (MRNA) – Analyst Ratings
-
Moderna (MRNA) Could Offset COVID Revenue via Rare Diseases - Morgan Stanley
-
Cowen Reiterates Market Perform Rating on Moderna (MRNA), 'there is a clear benefit to continued boosting'
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MRNA Stock Lookup